08:56 AM EDT, 04/17/2024 (MT Newswires) -- Health care stocks were mixed premarket Wednesday as the Health Care Select Sector SPDR Fund (XLV) was up 0.3% and the iShares Biotechnology ETF (IBB) was 0.3% lower recently.

Sage Therapeutics ( SAGE ) was declining by over 17% after saying the phase 2 study of its investigational drug dalzanemdor for the treatment of mild cognitive impairment in patients with Parkinson's Disease failed to meet its primary endpoint and did not demonstrate "any meaningful differences" in the other exploratory endpoints compared with placebo.